Weight-Based Pricing Experiments: GLP-1 Providers Charging by Starting BMI

Updated July 17, 2026

Most GLP-1 telehealth providers charge a flat monthly rate regardless of starting weight. But a handful have begun experimenting with pricing tied to BMI or total body weight, arguing that heavier patients require longer treatment courses, higher maintenance doses, and more provider oversight. Here is what those experiments look like and whether they actually change what you pay.

How Traditional GLP-1 Pricing Works

The standard model across the compounded telehealth market is dose-based pricing. You pay one rate at the starting dose (typically 0.25mg semaglutide or 2.5mg tirzepatide), and your cost may increase as you titrate to higher doses. The rate does not vary based on your starting weight, BMI, or projected treatment duration.

This approach is simple and transparent, which is why it dominates the market. Providers can publish a single price sheet. Patients can calculate their expected cost before enrolling. The downside is that it does not account for the reality that a patient starting at BMI 45 will likely need a longer and more intensive treatment course than one starting at BMI 31.

The BMI-Adjusted Models

The weight-based pricing experiments we have tracked fall into three categories:

Intake-adjusted plan recommendations. The most common approach is not technically variable pricing — it is intake-driven plan selection. After submitting health information including current weight and height, the provider's platform recommends a specific plan tier. Higher-BMI patients may be directed toward longer commitment plans (6 or 12 months) that lock in a lower per-month rate, while lower-BMI patients may see shorter plans offered. The per-month medication cost is the same either way; the behavioral nudge is toward a commitment length matched to likely treatment duration.

Dose-escalation pricing tiers. Some providers charge more at higher dose levels, which functions as implicit weight-based pricing because heavier patients typically require higher doses. A program might charge $179 per month for doses up to 1mg semaglutide and $249 per month for doses above 1mg. Since patients with higher starting BMI are more likely to reach and stay at higher doses, they effectively pay more over their treatment course.

True BMI-gated pricing. The rarest model, and one we have seen only in limited pilot form. In this approach, the monthly rate is explicitly different based on starting BMI bracket. A patient at BMI 32 might pay $199 per month; a patient at BMI 42 might pay $249 per month for the same medication. The provider's rationale is that higher-BMI patients require more provider time and higher cumulative doses.

What Providers Currently Do

Of the providers on our comparison list, none currently runs an explicit BMI-gated pricing model. The dose-escalation approach (higher price at higher doses) is the closest approximation, and it is used by a small number of providers — most notably programs that increase rates when patients reach maintenance doses above certain thresholds.

The Math on Dose-Escalation

To understand how dose-based pricing acts as a proxy for weight-based pricing, consider a typical semaglutide titration path:

A patient starting at BMI 31 might reach their target weight at 1mg per week after 6 months and begin a maintenance taper. Total cost at $199 per month: approximately $1,194.

A patient starting at BMI 42 might need 2.4mg per week, reaching it at month 8 and maintaining for another 6 months. If the provider charges $249 per month above 1mg, their total cost over 14 months is approximately $2,644 — more than double, driven by both longer duration and higher-dose pricing.

The question is whether that difference reflects a proportional difference in provider cost or whether it is simply margin capture on patients who have fewer alternatives.

Our Recommendation

For patients at any BMI, flat-rate pricing models offer the most predictable cost structure. Gala's $179-per-month flat rate across all doses is the clearest example — what you pay at 2.5mg tirzepatide is what you pay at 15mg. For semaglutide, look for providers that do not impose dose-escalation surcharges after you titrate past 1mg.

If you are starting at a higher BMI and anticipate a longer treatment course, commitment-length discounts (6-month or annual plans) matter more than per-dose pricing. The total-cost difference between a 6-month and 12-month plan at $50-per-month savings is $600 — a meaningful number regardless of BMI bracket.

Methodology: BMI pricing models described reflect our market research as of July 17, 2026. No provider on our comparison list currently operates an explicit BMI-gated pricing model. Dose-escalation pricing examples are illustrative based on published tier structures. Confirm current pricing directly with providers.